These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110 [TBL] [Abstract][Full Text] [Related]
18. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL Clin Pharmacokinet; 2020 Jan; 59(1):1-5. PubMed ID: 31432471 [TBL] [Abstract][Full Text] [Related]
19. [The simplex-method for optimizing tablet formulations in practical experience (author's transl)]. Beyer C Arch Pharm (Weinheim); 1978 Feb; 311(2):128-31. PubMed ID: 646588 [No Abstract] [Full Text] [Related]